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In the normal heart, cardiac fibroblasts are localized in the interstitium between 
cardiomyocytes where they are relatively quiescent and play a supportive role in cardiac 
homeostasis. When the heart is stressed or injured, fibroblasts become activated and 
migrate to damaged regions where they proliferate and facilitate wound healing and repair.1 
Cardiac fibroblasts exhibit a high level of plasticity and are able to adopt a number of 
different phenotypes during the remodeling process, including differentiation into 
myofibroblasts. The topology of fibroblasts in the normal heart, in which cells are largely 
separated from one another, is therefore very different from the remodeling heart, in which 
clustering of myofibroblasts occurs due to a combination of cell migration, proliferation and 
differentiation.  
The article published by Yu et al2 in the current issue of Circulation Research proposes 
that simple topological rearrangement of cardiac fibroblasts from a 2D environment to a 3D 
spherical cluster is sufficient to induce chromatin remodeling and gene expression changes 
that correlate with those observed in the remodeling heart in vivo, and importantly are 
associated with indices of adverse cardiac remodeling (see Figure). 
Accurate identification of cardiac fibroblasts has been confounded by a lack of cell-
specific markers for this cell type. Much of our historical knowledge on the role of cardiac 
fibroblasts in vivo has used markers such as vimentin, Thy1 and FSP1; but these proteins 
are also expressed by a range of other cardiac cell types.3 The advent of fluorescent 
lineage-tracing technologies has transformed our understanding of the role and fate of 
cardiac fibroblasts in cardiac development, physiology and pathophysiology. Several mouse 
lines have been generated that enable fibroblasts and myofibroblasts to be accurately traced 
over time in the remodeling heart.4,5 These studies have provided important new insights into 
the localization, phenotypic conversion and importance of fibroblasts in the remodeling heart.  
The article by Yu et al2 used 2D and 3D in vitro cell culture techniques, combined with in-
depth profiling of gene expression (RNA-Seq) and chromatin accessibility (ATAC-Seq), to 
demonstrate that simple topological rearrangement of cardiac fibroblasts into 3D spherical 
clusters can induce changes akin to those observed in the remodeling heart. The differential 
gene expression signatures between 2D and 3D cultures were reversible, reflecting the 
remarkable plasticity of this cell type. Important controls confirmed that these changes were 
not simply due to differences in tension/stiffness of the environment between 2D cultures 
and 3D aggregates. Gene ontology analysis highlighted patterns of genes that were down-
regulated (DNA replication, chromosomal condensation/segregation, cytokinesis) and up-
regulated (ECM metabolism/proteolysis, surface proteins, chemotaxis and immune 
response) in the 3D fibroblast clusters compared with the 2D cultures. Follow-up studies 
confirmed that 3D-aggregated cells exhibited markedly reduced proliferation, reduced 
expression of contractile proteins (e.g. the myofibroblast marker DSMA), reduced collagen 
expression, increased MMP expression and increased polarity. The latter point suggests that 
3D fibroblast aggregates have features of aligned topology, as observed for myofibroblasts 
in the infarct border zone.6   
The in vivo relevance of the 3D fibroblast clusters was investigated by comparing in vitro 
RNA-Seq gene expression signatures with those of the remodeling heart (using a data 
reduction method involving generation of principle component eigengenes). The authors 
used two different models of cardiac remodeling; an isoproterenol infusion heart failure 
model and a cryo-injury model to mimic myocardial infarction (MI). For the isoproterenol 
model, an extensive study was undertaken using 96 genetically diverse mouse strains 
(Hybrid Mouse Diversity Panel), an approach designed to enable genome-wide association 
analysis of phenotypic traits. Data were collected on the severity of cardiac hypertrophy and 
heart failure, and ventricular RNA extracted for gene expression analysis to compare with 
2D/3D cultures. Significant correlations were observed between the eigengene 3D gene 
signatures and adverse cardiac indices (e.g. hypertrophy, dilatation). It is worth noting that 
ventricular RNA from isoproterenol-infused mice was extracted from intact tissue rather than 
specifically from fibroblasts so would also contain RNA from other cardiac cell populations. 
Nevertheless, the results still provided a strong correlation between the fibroblast 3D 
signature and adverse cardiac parameters. For the cryo-injury model, the authors used 
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fibroblast lineage-tracing reporters to identify aggregated fibroblasts 7 days after injury and 
correlated this with expression of some of the 3D-upregulated proteins (e.g. MMP-11). 
Optical clearing of the hearts combined with confocal microscopy also highlighted 
association of aggregated fibroblasts with 3D-upregulated markers. Whilst these 
confirmatory experiments are generally supportive of the complex in vitro data, their limited 
focus on a very small number of selected targets did not capture the true importance of the 
gene signatures.        
Cardiac fibroblasts play a critical role in modulating cardiomyocyte hypertrophy through 
paracrine secretion of growth factors and other secreted molecules.7,8 The authors used live 
cell interferometry to show that neonatal rat ventricular myocytes underwent hypertrophy in 
response to conditioned media collected from cardiac fibroblast cultures, and that 
importantly the hypertrophic effect was larger in response to media from 3D cultures 
compared with 2D cultures.2 Thus, the secretome from aggregating cardiac fibroblasts may 
directly contribute to cardiac hypertrophy after myocardial injury.    
 The study by Yu et al2  raises several important questions, the most fundamental 
being: what is the in vivo cardiac fibroblast phenotype that is represented by the in vitro 3D 
fibroblast aggregates? Fibroblasts are known to adopt a range of phenotypes at various 
stages after MI.3 Recent experiments by Fu et al9 used multiple fibroblast lineage-tracing 
Cre-expressing mouse lines, combined with mRNA profiling and confocal 
immunohistochemistry, to more precisely define fibroblast differentiation states in the post-MI 
heart. These were described as µquiescent¶ (pre-injury), µactivated¶ (day 2-4 post-MI), 
µmyofibroblast¶ (day 4-7 post-MI) and µPDWULILEURF\WH¶ (day >10 post-MI); the latter being a 
highly differentiated, non-proliferating cell with a tendon-like gene signature important for 
maintaining scar integrity. How the 3D aggregates of cardiac fibroblasts described in the 
article by Yu et al2 correlate with these phenotypes is not immediately clear. The 3D gene 
signature included reduced DSMA, increased MMPs, increased inflammatory factors and 
reduced fibrotic factors. These hallmarks are similar to those observed in cardiac fibroblasts 
following stimulation with proinflammatory cytokines,10 representing the early inflammatory 
phase of post-MI remodeling (days 1-2) prior to fibroblast activation.3 However, the 
correlation in gene signatures between 3D-clustered cells and remodeling hearts (3 weeks 
isoproterenol infusion or 7 days after cryo-injury) indicate the 3D signature represents later 
phases of remodeling at a time when myofibroblasts are prevalent. In this regard, the 
decrease in DSMA expression observed between 2D and 3D cultures is perplexing as DSMA 
is characteristic of the myofibroblast phenotype. It would certainly be interesting to know 
whether the gene signature of the 3D clustered fibroblasts (reduced proliferation, reduced 
DSMA, reduced ECM synthesis) correlates with that of the newly described matrifibrocytes9 
that are present in mature scars, as these phenotypes, at least on first impression, appear 
similar.  
      MMP-11 (stromelysin-3) was one of the most highly up-regulated genes in 3D fibroblast 
clusters, and was studied further in vivo.2 The matrix metalloproteinases are a large family of 
zinc-dependent endopeptidases that together can degrade all components of the ECM. 
Cardiac fibroblasts express several different MMPs that are important for remodeling the 
cardiac ECM after injury.11 MMP-11 is unusual in that it is secreted in an active form (unlike 
other MMPs that are secreted as zymogens) and acts primarily on non-ECM components. 
This MMP has not been well-studied in the heart, although there is evidence that its 
ventricular expression is differentially regulated by hypoxia.12 MMP-11 has been more 
extensively studied in the cancer field; it is elevated in solid tumor biopsies and in the sera of 
cancer patients, and plays a role in development and progression of solid tumors.13 Obvious 
parallels can be drawn between the aggregation of cancer cells and clustering of cardiac 
fibroblasts in this respect. Future studies with cardiac fibroblast-specific deletion of MMP-11 
would be helpful in determining whether this protease is truly an important player in 
regulating fibroblast function and cardiac remodeling. 
 In summary, the study by Yu et al2 presents interesting new data using a range of 
novel techniques that suggest that cardiac fibroblast aggregation per se is sufficient to drive 
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phenotypic changes that contribute to the cardiac remodeling process. Further analysis of 
the 3D gene signatures with respect to known phenotypes of cardiac fibroblasts in the 
remodeling heart will be important to decipher the true importance of cell clustering in 
regulating fibroblast differentiation and remodeling. Such analyses may in turn identify novel 
targets for developing therapeutic agents to reduce adverse cardiac remodeling after 
myocardial injury.   
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Figure. Role of cardiac fibroblast aggregation on phenotype. 3D clustering of cardiac 
fibroblasts in vitro drives gene expression changes associated with reduced proliferation, 
reduced ECM synthesis and reduced expression of contractile proteins. Conversely, gene 
networks involved with ECM degradation, polarity, chemotaxis and immune response are 
increased. 3D-clustered cardiac fibroblasts are more potent inducers of cardiomyocyte 
hypertrophy than 2D cultures. These features are reversible in vitro (dashed arrow). 
Overlapping gene signatures were observed in remodeled cardiac tissue from in vivo models 
of heart failure and myocardial infarction. Moreover, 3D gene signatures were associated 
with indices of adverse remodeling. 
